TP63 and neoplasm: 31.6% patients showed TP63 immunoreactivity in the nucleoli of tumor cells with 1.3% case of weak positive, 13.1% of moderate, and 17.2% of strong positive (Supplemental Table S1, Fig. 1G and H).